Supercede

InsurTech · Reinsurance
Sponsors visas
5EmployeesUK accounts · Feb 2026 · +25% in a year

Facts

as of Nov 17, 2026

Supercede is the leading reinsurtech platform, streamlining reinsurance with advanced data management and deal-making tools for superior outcomes.

Legal name
SUPERCEDE LTDactive
Headquarters
Cleckheaton, United Kingdom
Founded
2019
Employees
5UK accounts · Feb 2026 · +25% in a year
Register numbers
CRN 11805154
Official records
Companies House 11805154
Website
supercede.com

These are the key facts about Supercede on Alion as of Nov 17, 2026. Supercede is headquartered in Cleckheaton, United Kingdom. It was founded in 2019.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
SUPERCEDE LTD
Yes
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Named in the work visa registers of United Kingdom.

A-ratedSponsor licence
Skilled WorkerVisa route
0Open roles in United Kingdom

In the register as SUPERCEDE LTD, Cleckheaton, WEST YORKSHIRE

Other sponsors in the same field
Alert me
UK Home Office · checked Nov 17, 2026

Footprint

Hiring in 2 cities in 1 country.

2Cities
1Countries
Loading the map
SiteTypeOpen rolesHires most forEngineering
Cleckheaton United KingdomHeadquarters0
London United KingdomRegional office0
Source: office addresses in postings and company registers

Milestones

Feb 4, 2019
Founded per the company register
Each milestone is dated by its source: registers, filings, the press

Newsroom

top 0.75%Web presenceof 133.2M domains by links, Common Crawl
Jun 24, 20252025
News · bioworld.com
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity. Supercede's lead can…
Sources: the outlets named on each headline, each story once